Cancer patients less protected after first vaccine jab, UK study finds

Cancer patients less protected after first vaccine jab, UK study finds
LONDON: Cancer patients may not be as protected as the rest of the population after receiving their first of two doses of a Covid-19 vaccine, a new UK study on Thursday found.
A team of experts from King & # 39; s College London and Francis Crick Institute found in the first real-world study of its kind that a shorter than the prescribed 12-week period between the two vaccine doses seemed to be the answer for such patients.
The study's senior authors, Dr Sheeba Irshad and Professor Adrian Hayday, believe there is an urgent need to re-evaluate UK dosing interval policies for all cancer patients, as well as many other high-risk immunosuppressed groups.
"Our data provides the first real-world evidence of single-dose immune efficacy of the Pfizer vaccine in immunocompromised patient populations," said Dr. Sheeba Irshad, a senior clinical lecturer in the School of Cancer and Pharmaceutical Sciences at King's College. London.
“We show that after the first dose, most solid and haematological cancer patients remained immunologically unprotected for at least five weeks after the primary injection; but this single dose poor efficacy can be saved with an early booster on day 21, ”she said.
Data from the world's first reported trial to examine the level of immune protection after the Pfizer / BioNTech vaccine in cancer patients has shown that anti-SARS-CoV-2 – the virus that causes Covid-19 – produces antibody responses in week three after the first dose of the vaccine were only 39 percent and 13 percent in the solid and hematologic cancers, compared with 97 percent in those without cancer.
The preprint study, which is to be peer-reviewed, also reports that when the second dose of the vaccine was given three weeks after the first dose, the immune response significantly improved for patients with solid cancer, with 95 percent of them showing detectable antibodies against it. SARS-CoV-2 virus in just two weeks.
In contrast, those who did not get a vaccine boost after three weeks saw no real improvement, with only 43 percent of solid cancer patients and 8 percent of blood cancer patients developing antibodies to the Pfizer vaccine after five weeks, compared to 100 percent of healthy controls .
Evidence of vaccine responses in cancer patients shows that a 12-week interval between doses of the Pfizer-BioNTech vaccine could leave many cancer patients vulnerable to severe Covid-19, the study finds.
Prof. Adrian Hayday from King & # 39; s College London and the Francis Crick Institute said: and caregivers can have confidence in their environment. "
Dr Simon Vincent, Director of Research, Support and Influence at Breast Cancer Now, called on the Joint Committee on Vaccination and Immunization (JCVI), which determines vaccine rollout cohorts in the UK, to urgently review and consider the evidence. strategy to ensure that cancer patients can receive both the first and second doses of the Pfizer / BioNTech Covid-19 vaccine within three weeks to reduce their risk of both contracting and becoming seriously ill with the coronavirus. minimalize.
“It is worrying that this study suggests that people with cancer, including breast cancer, get little protection against the virus if they get just a single dose of the Pfizer Covid-19 vaccine and then don't get their vaccine boost in the next three weeks. ," he said.
But Cancer Research UK said the small study had not yet been reviewed by other scientists and that people undergoing cancer treatment should continue to follow the advice of their doctors, while the government said the antibody response was "only part of the protection afforded by it. vaccine is offered ". .
Meanwhile, the UK study will continue to monitor cancer patients after their vaccinations for up to six months.

. (tagsToTranslate) vaccine (t) pfizer / biontech (t) cancer research (t) cancer patients (t) cancer

Leave a Reply

Your email address will not be published. Required fields are marked *